Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

N-Acetyl Cysteine and Improved Parkinson's Disease Symptoms

Doses used in studies

mg/kg/week: 50 (median 50, IQR 50–50) — 1 study

Time to effect

Median: 6 months · IQR 6 months–6 months · Range 6 months–6 months — Reported in 1 of 1 study

1 of 1 paper

N-Acetylcysteine is associated with changes in functional connectivity in patients with Parkinson's disease.
- 2026-03
- RCT
- Parkinsonism & related disorders 144
- - Daniel A Monti
  - George Zabrecky
  - Daniel Kremens
  - Tsao-Wei Liang
  - Nancy A Wintering
  - Faezeh Vedaei
  - Emily Navarreto
  - Monisha Gupta
  - Alicia Steinmetz
  - Anthony J Bazzan
  - Feroze Mohammed
  - Andrew B Newberg
- PubMed: 41619526
- DOI: 10.1016/j.parkreldis.2026.108216
2 Insights on
- Improved Parkinson's Disease Symptoms
- High evidence
- Clinical
Changes in the precuneus also correlated with changes in UPDRS scores.
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
50 mg/kg weekly IV + 500 mg twice per day oral